Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-guided therapy with GS-5885 alone or with GS-9451 plus peginterferon alfa-2a and ribavirin in treatment-naïve chronic genotype 1 HCV
2011-000456-42Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatitis C virus infection comparing GS-5885 + GS-9451 + peginterferon alfa-2a + ribavirin, GS-5885 + peginterferon alfa-2a + ribavirin and Peginterferon alfa-2a + ribavirin + placebo (3 arms). Primary endpoint: Sustained virologic response (SVR). Started May 2011; status: completed.
02
Drugs
ledipasvirvedroprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-000456-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000456-42.